Top Markets
Coin of the day
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Pozycja w akcjach #18406
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Cena akcji
$5.81
Ostatnia synchronizacja: 2023-02-28
Kapitalizacja rynkowa
$200.14M
Zmiana (1 dzień)
-0.34%
Zmiana (1 rok)
0.00%
Kraj
US
Handel KemPharm, Inc. (KMPH)

Kategoria

EPS dla KemPharm, Inc. (KMPH)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy KemPharm, Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla KemPharm, Inc. od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH